Evidence map›Paper›PMID 33673598›Full record

ArticleMolecules (Basel, Switzerland)2021

MCH-R1 Antagonist GPS18169, a Pseudopeptide, Is a Peripheral Anti-Obesity Agent in Mice.

Jean A Boutin, Magali Jullian, Lukasz Frankiewicz, Mathieu Galibert, Philippe Gloanec, Thierry Le Diguarher, Philippe Dupuis, Amber Ko, Laurent Ripoll, Marc Bertrand and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Jean A BoutinInstitut de Recherches Internationales Servier, 92284 Suresnes, France.ORCID 0000-0003-0068-7204
Magali JullianGenepep SA, 34430 Saint Jean de Vedas, France.
Lukasz FrankiewiczGenepep SA, 34430 Saint Jean de Vedas, France.
Mathieu GalibertGenepep SA, 34430 Saint Jean de Vedas, France.
Philippe GloanecInstitut de Recherches Servier, 92150 Suresnes, France.
Thierry Le DiguarherTechnologie Servier, 45520 Gidy, France.
Philippe DupuisEurofins Discovery, 86600 Celle l'Evescault, France.
Amber KoEurofins Discovery, New Taipei City 24891, Taiwan.
Laurent RipollInstitut de Recherches Internationales Servier, 92284 Suresnes, France.
Marc BertrandTechnologie Servier, 45520 Gidy, France.
Anne PecqueryEurofins Discovery, 86600 Celle l'Evescault, France.
Gilles FerryInstitut de Recherches Servier, 78290 Croissy-sur-Seine, France.
Karine PugetGenepep SA, 34430 Saint Jean de Vedas, France.
Servier (France) · FREurofins (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanin-concentrating hormone (MCH) is a 19 amino acid long peptide found in the brain of animals, including fishes, batrachians, and mammals. MCH is implicated in appetite and/or energy homeostasis. Antagonists at its receptor (MCH-R1) could be major tools (or ultimately drugs) to understand the mechanism of MCH action and to fight the obesity syndrome that is a worldwide societal health problem. Ever since the deorphanisation of the MCH receptor, we cloned, expressed, and characterized the receptor MCH-R1 and started a vast medicinal chemistry program aiming at the discovery of such usable compounds. In the present final work, we describe GPS18169, a pseudopeptide antagonist at the MCH-R1 receptor with an affinity in the nanomolar range and a Ki for its antagonistic effect in the 20 picomolar range. Its metabolic stability is rather ameliorated compared to its initial parent compound, the antagonist S38151. We tested it in an in vivo experiment using high diet mice. GPS18169 was found to be active in limiting the accumulation of adipose tissues and, correlatively, we observed a normalization of the insulin level in the treated animals, while no change in food or water consumption was observed.

Indexed as

Adipose TissueAlkynesAminobutyratesAnimalsAnti-Obesity AgentsAppetiteAspartic AcidDisease Models, AnimalDrug DiscoveryGlutamic AcidGlycineHEK293 CellsHepatocytesHomeostasisHumansInsulinAlkynesalpha-aminobutyric acidAminobutyratesAnti-Obesity AgentsAspartic AcidGlutamic AcidGlycinehomopropargylglycineInsulinLactamsmelanin-concentrating hormone receptorReceptors, Pituitary HormoneTriazolesdiet-induced obesityMCHMCH-R1 antagonistpseudopeptidetreatment

Identifiers

PMID33673598
PMCPMC7957705
OpenAlexW3135139687

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.